MABVAX THERAPEUTICS HOLDINGS, INC.
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX): 3 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
D/E 208.06 · 85% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for MABVAX THERAPEUTICS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$952K
Quarterly Burn
$2.7M
Runway
1.2 mo
Revenue
$4.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in MABVAX THERAPEUTICS HOLDINGS, INC.'s pipeline?
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MABVAX THERAPEUTICS HOLDINGS, INC.'s lead drug candidate?
MABVAX THERAPEUTICS HOLDINGS, INC.'s most advanced tracked candidate is mvt-1075 (Phase 1) for Locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies.
What is MABVAX THERAPEUTICS HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MABVAX THERAPEUTICS HOLDINGS, INC. has approximately 1.2 months of cash runway.
Get the full picture on MABVAX THERAPEUTICS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.